Vincenzo Accurso
Palermo, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Sequential TKI Treatment in Patients With Chronic Phase Chronic Myeloid Leukemia Resistant to Frontline Nilotinib or Dasatinib Therapy. A Real-Life Survey From the Italian Campus CML Network.
Journal: Clinical lymphoma, myeloma & leukemia
Published: June 09, 2026
How to read P-values and confidence intervals in public health studies.
Journal: Saudi journal of anaesthesia
Published: March 09, 2024
Ruxolitinib in patients with polycythemia vera resistant and/or intolerant to hydroxyurea: European observational study.
Journal: European journal of haematology
Published: May 26, 2023
An Improved Peer-Review System to Compensate for Scientific Misconduct in Health-Sensitive Topics.
Journal: Public health reviews
Published: November 18, 2022
Triple-Negativity Identifies a Subgroup of Patients with Better Overall Survival in Essential Thrombocythemia.
Journal: Hematology reports
Published: February 15, 2022
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report.
Journal: British journal of haematology
Published: July 11, 2021
Familial essential thrombocythemia: 6 cases from a mono-institutional series.
Journal: Clinical case reports
Published: July 10, 2021
Cardiovascular Issues in Tyrosine Kinase Inhibitors Treatments for Chronic Myeloid Leukemia: A Review.
Journal: Frontiers in physiology
Published: March 04, 2021
Antimicrobial prophylaxis in patients with immune thrombocytopenia treated with rituximab: a retrospective multicenter analysis.
Journal: Annals of hematology
Published: January 10, 2021
Isolated Nodal TBC Reactivation in a Patient with Post-Thrombocythemia Myelofibrosis Treated with Ruxolitinib: Case Report and Review of the Literature.
Journal: Chemotherapy
Published: November 25, 2020
The Essential Thrombocythemia in 2020: What We Know and Where We Still Have to Dig Deep.
Journal: Clinical medicine insights. Blood disorders
Published: October 19, 2020
Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs.
Journal: American journal of hematology
Published: May 06, 2020
Last Updated: 09/26/2026